<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618211</url>
  </required_header>
  <id_info>
    <org_study_id>PHA022121-C201</org_study_id>
    <secondary_id>2020-003445-11</secondary_id>
    <nct_id>NCT04618211</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema</brief_title>
  <acronym>RAPIDe-1</acronym>
  <official_title>A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharvaris Netherlands B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharvaris Netherlands B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of orally administered PHA-022121 for the acute treatment&#xD;
      of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to&#xD;
      one of three single doses of PHA-022121 and placebo. The study will compare symptom relief&#xD;
      (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of&#xD;
      PHA-022121 with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part I of the study, patients in non-attack state receive the assigned active single dose&#xD;
      of PHA-022121 at the study center to assess pharmacokinetics (the way the body absorbs,&#xD;
      distributes, and gets rid of the drug) and safety. In Part II of the study, patients&#xD;
      self-administer blinded study drug at home to treat three HAE attacks with PHA-022121 or&#xD;
      placebo (cross-over).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the 3-symptom composite visual analogue scale (VAS-3) score from pre-treatment to 4 hours post-treatment</measure>
    <time_frame>Pre-treatment and 4 hours post-treatment</time_frame>
    <description>VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of symptom relief by visual analogue scale (VAS-3) score</measure>
    <time_frame>Assessed from pre-treatment to 48 hours post-treatment</time_frame>
    <description>VAS-3 scores range between 0 and 100. Symptom relief is defined as a 50% or higher reduction of the VAS-3 score from the pre-treatment value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of study drug treated attacks requiring HAE rescue medication</measure>
    <time_frame>Assessed at 4 hours post-study drug treatment</time_frame>
    <description>Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 h has been experienced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of almost complete and complete symptom relief by visual analogue scale (VAS-3)</measure>
    <time_frame>Assessed from pre-treatment to 48 hours post-treatment</time_frame>
    <description>VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value &lt; 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean symptom complex severity (MSCS) score</measure>
    <time_frame>4 hours post-treatment</time_frame>
    <description>MSCS scores range between 0 and 3. A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment outcome score (TOS)</measure>
    <time_frame>Pre-treatment and 4 hours post-treatment</time_frame>
    <description>TOS scores range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction questionnaire for medication (TSQM) scores</measure>
    <time_frame>48 hours post-treatment</time_frame>
    <description>TSQM scores range from 0 to 100. A higher score means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From post-dose non-attack visit through study completion, approximately 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events (AEs)</measure>
    <time_frame>From post-dose non-attack visit through study completion, approximately 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent serious adverse events (TESAEs)</measure>
    <time_frame>From post-dose non-attack visit through study completion, approximately 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>Hereditary Angioedema Type I</condition>
  <condition>Hereditary Angioedema Type II</condition>
  <condition>Hereditary Angioedema Types I and II</condition>
  <condition>Hereditary Angioedema Attack</condition>
  <condition>Hereditary Angioedema With C1 Esterase Inhibitor Deficiency</condition>
  <condition>Hereditary Angioedema - Type 1</condition>
  <condition>Hereditary Angioedema - Type 2</condition>
  <condition>C1 Esterase Inhibitor Deficiency</condition>
  <condition>C1 Inhibitor Deficiency</condition>
  <arm_group>
    <arm_group_label>Low dose/placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single low dose of PHA-022121 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose/placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single medium dose of PHA-022121 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose/placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single high dose of PHA-022121 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHA-022121</intervention_name>
    <description>PHA-022121 soft capsules for oral use (PHVS416)</description>
    <arm_group_label>High dose/placebo</arm_group_label>
    <arm_group_label>Low dose/placebo</arm_group_label>
    <arm_group_label>Medium dose/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules for oral use</description>
    <arm_group_label>High dose/placebo</arm_group_label>
    <arm_group_label>Low dose/placebo</arm_group_label>
    <arm_group_label>Medium dose/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent form&#xD;
&#xD;
          2. Diagnosis of HAE type I or II&#xD;
&#xD;
          3. Documented history of HAE attacks: at least three in the last 4 months, or at least&#xD;
             two in the last 2 months prior to screening&#xD;
&#xD;
          4. Reliable access and experience to use standard of care acute attack medications&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast-feeding&#xD;
&#xD;
          2. Clinically significant abnormal electrocardiogram&#xD;
&#xD;
          3. Any other systemic disease or significant disease or disorder that would interfere&#xD;
             with the patient's safety or ability to participate in the study&#xD;
&#xD;
          4. Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens,&#xD;
             anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to&#xD;
             enrollment&#xD;
&#xD;
          5. Positive serology for HIV or active infection with hepatitis B virus or hepatitis C&#xD;
             virus&#xD;
&#xD;
          6. Abnormal hepatic function&#xD;
&#xD;
          7. Abnormal renal function&#xD;
&#xD;
          8. History of alcohol or drug abuse within defined period, or current evidence of&#xD;
             substance dependence or abuse&#xD;
&#xD;
          9. History of documented severe hypersensitivity to any medicinal product&#xD;
&#xD;
         10. Participation in any other investigational drug study within defined period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pharvaris Clinical Team</last_name>
    <phone>+31 (71) 203-6410</phone>
    <email>clinicaltrials@pharvaris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Monserrato</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <keyword>HAE Type I</keyword>
  <keyword>HAE Type II</keyword>
  <keyword>Oral Treatment</keyword>
  <keyword>Bradykinin B2 Receptor Antagonists</keyword>
  <keyword>PHVS416</keyword>
  <keyword>PHA121</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Hereditary Angioedema Types I and II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

